CELL AND GENE THERAPY

CSL Plasma Reimagines Donor Experience With First Donations Completed on Innovative Plasma Collection Technology

CSL Plasma | August 08, 2022 | Read time : 04:00 min

CSL Plasma
CSL Plasma, the plasma collection business of global biotherapeutics leader CSL Behring, began a new era in plasma donations, collecting its first plasma donations using leading-edge plasma collection technology that is expected to significantly reduce average collection time – by approximately one-third – and improve the donor experience. 

The Rika Plasma Donation System, only available at CSL Plasma and developed by Terumo Blood and Cell Technologies, is designed to reduce collection time, and improve the donor and operator experience. When considering prior average CSL Plasma donation procedure times, this could represent about a 30% reduction in average donation time for donors.  

The new plasmapheresis system first launched today in the Aurora, Colorado, CSL Plasma location, as part of a phased rollout to CSL Plasma U.S. collection centers. Plasma collected at CSL Plasma facilities is used in the manufacturing of lifesaving plasma-derived therapies.

"Today marks a threshold moment for plasma donors following years of dedication, innovation and collaboration – demonstrating how we are driven by our promise in delivering lifesaving and life-extending therapies to patients around the world. We look forward to the positive impact this new technology brings and are thankful for plasma donors who continue to do the amazing every day when they donate at CSL Plasma."

CSL Chief Operating Officer Paul McKenzie

CSL Plasma believes features of the new Rika system can enable the collection of more plasma, in shorter periods of time, supporting quality and safety, and, ultimately, better serving patients who rely on plasma-based therapies.

One of the first plasma donors to experience the Rika system, Kelly Geiser is a resident of the Denver area. She has donated plasma since 2017, and is a Platinum level donor as part of CSL Plasma's donor loyalty program, iGive Rewards®.

Geiser appreciated that she was able to complete the donation procedure with the new technology in under 35 minutes and in the fastest donation time she has experienced, while every plasma donor's experience will vary. Donating plasma is also personal for Geiser, who says that therapies made from plasma have helped her and her family, including a parent who recently underwent emergency surgery.

"It feels good knowing I'm helping people and, who knows, I might've helped somebody I know," said Geiser.

According to Terumo BCT, benefits of the Rika Plasma Donation System include


  • Rika completes one plasma collection in 35 minutes or less on average. The proprietary design of the system's centrifuge maximizes the plasma yield per cycle.
  • The Rika Plasma Donation System was designed to allow no more than 200 milliliters of blood cells outside the donor's body, resulting in a low extracorporeal volume, which may contribute to a more comfortable donor experience.
  • With less than 200 milliliters of blood cells outside the donor's body at any given time, should the initial procedure not be completed, the donor can return and donate without being deferred.


The device is designed with an advanced user interface to guide CSL Plasma front-line employees. Operators can quickly and confidently resolve alarms, thanks to guidance provided on the Rika system's touchscreen, which also alerts operators about situations that require attention and provides suggested actions to resolve the situation. The system allows for real-time data analytics to drive device maintenance and repairs. 

CSL Plasma is implementing the new devices at Colorado centers and then expanding to other U.S. locations, providing donors more opportunities to "do the amazing" and be rewarded for their generosity.

"As a long-time leader in our industry, CSL Plasma looks forward to this new plasmapheresis technology to delight our plasma donors and attract new donors while supporting a better operating experience for our employees," said Walter Charles, CSL Plasma Senior Vice President and General Manager. "As we complete the implementation of new technology at U.S. centers, we continue to address the critical and ongoing need for human plasma to produce life-saving medicines for people with serious and rare diseases."

About CSL Plasma
CSL Plasma operates one of the world's largest and most sophisticated plasma collection networks, with more than 300 plasma collection centers in the U.S., Europe and China. Headquartered in Boca Raton, Florida, CSL Plasma is a subsidiary of CSL Behring, a global biotherapeutics company and a member of the CSL Group of companies. Plasma collected at CSL Plasma facilities is used by CSL Behring for the sole purpose of manufacturing lifesaving plasma-derived therapies for people in more than 100 countries. The parent company, CSL Limited headquartered in Melbourne, Australia, employs more than 25,000 people. 

About CSL Behring 
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. Focused on serving patients' needs by using the latest technologies, we discover, develop and deliver innovative therapies for people living with conditions in the immunology, hematology, cardiovascular and metabolic, respiratory, and transplant therapeutic areas. We use three strategic scientific platforms of plasma fractionation, recombinant protein technology, and cell and gene therapy to support continued innovation and continually refine ways in which products can address unmet medical needs and help patients lead full lives. 

Spotlight

Zebrafish heartbeat taken with ImageXpress Micro XL System with transmitted light module.
Courtesy of Prof. Tanaka, Department of Molecular and Cellular Pharmacology, Pharmacogenomics and Pharmacoinformatics, Mie University Graduate School of Medicine, Mie, Japan.

Spotlight

Zebrafish heartbeat taken with ImageXpress Micro XL System with transmitted light module.
Courtesy of Prof. Tanaka, Department of Molecular and Cellular Pharmacology, Pharmacogenomics and Pharmacoinformatics, Mie University Graduate School of Medicine, Mie, Japan.

Related News

MEDTECH

Insempra Announces Strategic Investment in Solena Materials

Insempra, | July 26, 2022

Insempra, a biology-powered company enabling businesses to make superior products in partnership with nature, today announces a strategic investment in Solena Materials Ltd a synthetic biology company. Solena, a spin-out from Imperial College London, develops synthetic proteins for high-performance clothing fibers. The investment will allow Insempra, formerly Origin.Bio, to accelerate its strategy of harnessing new technologies to advance biological production processes, creating naturally superior products to drive the regenerative revolution. Solena will be a major part of Insempra’s platform to deliver high-performance, intrinsically sustainable ingredients for a broad array of industries. Solena is using computational design to develop new classes of synthetic proteins to produce high-performance clothing fibers, which can absorb large amounts of kinetic energy. Insempra will accelerate the development and production of these synthetic proteins on an industrial scale, offering better, biobased solutions to the petrochemically sourced, non-biodegradable materials or fibers extracted from nature or animals, such as silk, currently used in the textile and clothing industries. This technology also reduces other environmental impacts such as the rise of microplastics in water bodies coming from washing petrochemically-sourced textiles. “We are hugely excited by this investment in Solena, which will help to accelerate our market-first approach to develop superior, intrinsically sustainable ingredients. We look forward to fast-tracking Solena’s development and production of their unique synthetic proteins to develop customized, high-performance fibers for a variety of applications.” Jens Klein, founder and CEO of Insempra and CEO of Solena Materials Dr James MacDonald, inventor, co-founder and CTO of Solena Materials, added: “The team and I are very excited to make this technology a huge success.” Professor Paul Freemont of Imperial College London, added: “This investment from Insempra recognizes the potential of our technology to revolutionize high-performance fabrics, and their supply chains. Together, we can harness our synthetic biology capabilities to develop, produce and manufacture a new class of superior, more sustainable fiber technology.” Insempra, a co-founder of Solena, will be the sole contributing shareholder in Solena, which is based at Imperial College’s Translation & Innovation Hub (I-HUB) in White City, London. Solena’s Board will be comprised of Dr James MacDonald of Solena, Professor Paul Freemont and Professor Milo Shaffer of Imperial College London, and Jens Klein and Andreas Heyl of Insempra. About Insempra Insempra is a biology-powered company enabling businesses to make superior products with nature. We combine bioscience and technology to grow matter for new and better products. For too long, businesses have relied on chemical industrialization processes and petrochemicals, depleting our planet’s limited resources. That’s why we are committed to drive the regenerative revolution to manufacture at scale in collaboration with nature. Led by a hand-picked team of biologists, technologists and entrepreneurs with rebel hearts, Insempra is here to create a new school of thought and collective action. The time to restore the balance between people and the planet is now. We don't wait for change. We do what needs to be done to grow a better future. About Solena Materials Solena is a protein materials design company. We use world-leading computational design, machine learning, and automation to accelerate the development of bespoke materials targeted at multiple sectors, from fashion apparel to medical textiles. Our new protein-based fibers will replace materials extracted from nature such as silk and petrochemically-derived materials, to create a new world of biodegradable, functional and sustainable smart materials for consumers, industry, and the planet.

Read More

INDUSTRIAL IMPACT

BeiGene Announces Strategic Research Collaboration with InnoRNA to Jointly Discover Novel mRNA Therapies

InnoRNA and BeiGene | July 07, 2022

BeiGene a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide, announced it entered into a worldwide strategic collaboration with InnoRNA, a biotechnology company with expertise in LNP-based delivery technology and mRNA drug discovery, to leverage its innovative technology platform for developing mRNA-based therapeutics. “As a global biotechnology company, BeiGene is committed to delivering next-generation therapies through our own internal discovery engine and leveraging cutting-edge technology from experienced and innovative partners. This collaboration with InnoRNA advances and supports our research efforts in the important field of mRNA therapies while securing critical, proprietary delivery tools.” Lai Wang, Ph.D., Global Head of R&D at BeiGene Under the terms of the agreement, InnoRNA will receive an upfront cash payment and will be eligible to receive additional payments based upon the achievement of certain development, regulatory, and commercial milestones, as well as tiered royalties, for the mRNA-LNP research collaboration programs. BeiGene will hold exclusive global development and commercialization rights for the mRNA-LNP therapies jointly discovered by InnoRNA and BeiGene. InnoRNA will receive an additional upfront cash payment and is eligible for additional milestone payments for granting BeiGene non-exclusive license to its proprietary LNP Technology platform. “We are very excited to partner with BeiGene to discover and develop innovative mRNA therapies as well as contribute our LNP technology to BeiGene’s internal research,” said Linxian Li, Ph.D., Founder and Chief Executive Officer of InnoRNA. “As evidenced by the success of multiple Covid-19 vaccines, mRNA and LNPs will likely play a major role in the future of drug development, potentially in broad fields beyond vaccines. Joining this collaboration with BeiGene represents a big step forward toward this vision for our company.” About InnoRNA InnoRNA is a platform-based biotechnology company focused on developing innovative mRNA and LNP technologies to produce therapeutic proteins rapidly and accurately in cells. Faced with the challenge of delivering mRNA into the right cells, the existing carriers have been unable to maximize the potential of mRNA as a therapeutic tool to generate disease-fighting proteins. InnoRNA developed the proprietary Diversity-Oriented LNP platform to deliver mRNA safely and effectively into the cell of interest. The commercialization of this innovation presents a revolutionary step towards delivering effective and safe clinical mRNA treatments for societies everywhere. About BeiGene BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of over 8,000 colleagues across five continents.

Read More

INDUSTRIAL IMPACT

Heska to Acquire LightDeck Diagnostics to Invest in Manufacturing Capabilities and Accelerate Research and Development Efforts

LightDeck Diagnostics and Heska | September 13, 2022

Heska Corporation a leading global provider of advanced veterinary diagnostic and specialty solutions, announced today that the Company has entered a definitive agreement to acquire 100% of the share capital of MBio Diagnostics, Inc. d/b/a LightDeck Diagnostics a pioneer in innovative planar waveguide fluorescence immunoassay diagnostics with strong manufacturing and specialized production capabilities. Founded in 2009 and headquartered in Boulder, Colorado, LightDeck has developed a scalable and innovative platform for rapid and accurate point of care diagnostics. LightDeck's 80-member team includes industry veterans, engineers, and scientists, with deep technical expertise in assay development, manufacturing, and software development, who have collaborated with commercial, academic, and government partners worldwide to build an extensive intellectual property portfolio of 16 US patents and 15 international patents with broad applications, including in veterinary diagnostics, water testing, and human in-vitro diagnostics use. LightDeck's planar waveguide technology optimizes laser activated fluorescence and microfluidics to provide point of care cartridge-based testing without compromise, enabling reference lab-quality results in minutes with inexpensive, quantitative, and easy-to-use functionality. LightDeck's current Boulder location includes fully equipped laboratories for assay development and controlled manufacturing capabilities that support its new, state-of-the-art, highly automated facility in Longmont, Colorado, anticipated to go online in 2023 to dramatically scale-up capacity, production, and research and development. "We are thrilled to welcome the entire LightDeck team to Heska. We have known and closely followed their success for years and we are happy to fully join with them today as one team focused on supercharging their great work. LightDeck brings to Heska best-in-breed, highly scalable manufacturing and world-class assay development to help drive our strategies for winning at innovation and winning at scale," commented Kevin Wilson, Heska's Chief Executive Officer and President. "LightDeck was central in developing Heska's leading immunodiagnostic platform, Element i+®, including its current menu of Total T4, cTSH, Cortisol, and Progesterone. Having proven our capability, we now take this next important step as we aim to drive production of Element i+® analyzers and cartridges at scale and to accelerate key test menu expansion, such as our recently announced Nu.Q® Vet Cancer Screen, cCRP, SDMA, infectious diseases, and more, in single and multi-plex formats that are substantially better than the competition. We expect to drive gross margin improvement with new manufacturing capabilities and scaling across the business. The addition of LightDeck is a great strategic, financial, and cultural fit with Heska as we continue our march to the top of the innovation and manufacturing competition for the most valuable diagnostics," concluded Mr. Wilson. "This is a terrific outcome for LightDeck and Heska and their shareholders, employees and commercial partners. We have known and worked with Heska for years and we greatly admire the Heska organization. Since its founding in 2009, LightDeck has been dedicated to revolutionizing testing at the point of care- for faster, more accurate, less expensive, multi-plex testing of the most important diagnostic tests. We have developed one of the most innovative and technologically-advanced assay platforms in the world, which has led to our recent addition to Fast Company's Annual List of the World's 50 Most Innovative Companies for 2022. I am very proud of the work our team has accomplished over the last 13 years." LightDeck's Co-Founder and Chief Technology Officer, Mike Lochhead, went on to say, "We are excited to now enter this next phase with Heska to dramatically expand our reach and scale. What we do at LightDeck matters a great deal. With Heska, we go confidently into our next commercial, manufacturing, and development chapters, strongly engaged, highly supported, and clearly set-up for long-term success and growth." Nick Traggis, LightDeck's Chief Executive Officer About Heska Heska Corporation manufactures, develops and sells advanced veterinary diagnostics, informatics, and specialty healthcare solutions through its two business segments: North America and International. Both segments include Point of Care Lab testing instruments and consumables, digital imaging products, software and services, data services, allergy testing and immunotherapy, and single-use offerings such as in-clinic diagnostic tests and heartworm preventive products. The North America segment also includes private label vaccine and pharmaceutical production for third-parties, primarily for herd animal health. About LightDeck Diagnostics LightDeck Diagnostics believes in a new approach to healthcare, where quick and accurate diagnostic tests will be run wherever and whenever they are needed. The company's proprietary LightDeck® platform combines an advanced laser waveguide with novel materials and patented manufacturing techniques to deliver lab-quality results anywhere, in minutes. The LightDeck platform is achieving success in veterinary diagnostics and for environmental testing. LightDeck is also developing a portfolio of in vitro diagnostic panels. The company is based in Boulder, Colorado, and is recognized as Colorado BioScience Association's Company of the Year, 2021.

Read More